Indian injectables specialist Gland Pharma is aiming to establish a secondary manufacturing site for some of Chinese manufacturer Shanghai Henlius Biotech’s “key” biosimilar products, after signing an initial collaboration agreement with the firm that could begin to bear fruit in the coming years.
Gland Pharma Mulls Second Site After Penning Initial Henlius Biosimilar Deal
Cost Of Up To $100m Envisioned Via Capacity Expansion; Follows Reddy’s Partnership
India’s Gland Pharma had much to discuss during its financial third-quarter earnings call, including a recent CDMO partnership with China’s Shanghai Henlius Biotech that could lead to the establishment of further manufacturing space to meet demand.
